Patent Application
20130065903
The present invention is generally directed to cardiac treatment and therapy, and more particularly to a method of treating, preventing, reversing, or ameliorating diastolic dysfuntion.
Hypertension is the most common risk factor for diastolic dysfunction in humans, which can lead to heart failure with preserved ejection fraction (Reference 1). This type of heart failure is increasing, and accounts for significant mortality and healthcare expenditures (References 1 and 2). Current treatments for diastolic dysfunction are inadequate, partially because the mechanism of altered myocardial relaxation is incompletely understood (Reference 3). Nitric oxide (NO) generated by NO synthase (NOS) is a critical modulator of cardiac relaxation (Reference 4), and NO bioavailability is regulated by tetrahydrobiopterin (BH4) (Reference 5).
Under physiological conditions, NOS catalyzes the production of NO from L-arginine to modulate myofilament contractility through mechanisms that are not clear (References 6-9). BH4 depletion, leads to NOS uncoupling (References 5 and 10), the production of superoxide instead of NO, and diastolic dysfunction (References 5 and 11). BH4 supplementation reverses these effects. Recently, we have reported that diastolic dysfunction was characterized by altered myofilament properties and by S-glutathionylation of cardiac myosin binding protein-C (MyBP-C) (Reference 12). S-glutathionylation is an oxidative post-translational modification of protein cysteines by the addition of the anti-oxidant tripeptide glutathione (References 13-15). We tested whether the improvement in diastolic dysfunction with BH4 treatment correlated with changes in myofilament properties and in S-glutathionylation of cardiac MyBP-C.
The present disclosure is directed to various aspects of the present invention.
One aspect of the present invention is demonstration that by depressing or reducing S-glutathionylation of myosin binding protein-C (MyBP-C), tetrahydrobiopterin (BH4) ameliorates diastolic dysfuntion by reversing a decrease in myofilament cross-bridge kinetics or restorating to normal thereof.
Another aspect of the present invention is demonstration of cardiac relaxation modulation by post-translational modification of myofilament proteins.
Another aspect of the present invention is demonstration that hypertension-induced diastolic dysfunction is characterized by reduced myofilament cross-bridge kinetics that are reversed by BH4, and that the effect of BH4 correlates with a reduction in glutathionylation of MyBP-C, suggesting that this post-translational modification may lead to diastolic dysfunction and that BH4 treatment may work by preventing this oxidative modification.
Another aspect of the present invention is a method of treating, preventing, reversing, or ameliorating diastolic dysfunction, which includes reducing S-glutathionylated myosin binding protein-C (MyBP-C) level by administering to a host in need thereof a therapeutically effective amount of tetrahydrobiopterin (BH4).
Another aspect of the present invention is a method of treating, preventing, reversing, or ameliorating diastolic dysfunction, which includes reversing changes in myofilament cross-bridge kinetics level by administering to a host in need thereof a therapeutically effective amount of tetrahydrobiopterin (BH4).
Another aspect of the present invention is a method of treating, preventing, reversing, or ameliorating diastolic dysfunction, which includes restoring myofilament cross-bridge kinetics to normal level by administering to a host in need thereof a therapeutically effective amount of tetrahydrobiopterin (BH4).
Another aspect of the present invention is a method of treating, preventing, reversing, or ameliorating diastolic dysfunction, which includes modulating post-translational modification of myosin binding protein-C (MyBP-C) level by administering to a host in need thereof a therapeutically effective amount of tetrahydrobiopterin (BH4).
Another aspect of the present invention is a method of treating, preventing, reversing, or ameliorating diastolic dysfunction in a host with manganese superoxide dismutase (MnSOD) deficiency, which includes administering to the host a therapeutically effective amount of tetrahydrobiopterin (BH4).
One of the above and other aspects, novel features and advantages of the present invention will become apparent from the following detailed description of the non-limiting preferred embodiment(s) of invention, illustrated in the accompanying drawings, wherein:
A few preferred embodiments of the present invention are described in detail sufficient for one skilled in the art to practice the present invention. It is understood, however, that the fact that a limited number of preferred embodiments are described herein does not in any way limit the scope of the present invention.
Recently, we reported that hypertension-induced diastolic dysfunction was accompanied by cardiac BH4 depletion, NOS uncoupling, a depression in myofilament cross-bridge kinetics, and S-glutathionylation of myosin binding protein C (MyBP-C). We hypothesized that the mechanism by which BH4 ameliorates diastolic dysfunction is by preventing glutathionylation of MyBP-C and thus reversing changes of myofilament properties that occur during diastolic dysfunction. We used the deoxycorticosterone acetate DOCA)-salt mouse model, which demonstrates mild hypertension, myocardial oxidative stress, and diastolic dysfunction.
As noted in more detail below, the mice were divided into two groups that received control diet and two groups that received BH4 supplement for 7 days after developing diastolic dysfunction at post-operative day 11. Mice were assessed by echocardiography. Left ventricular papillary detergent-extracted fiber bundles were isolated for simultaneous determination of force and ATPase activity. Sarcomeric protein glutathionylation was assessed by immunoblotting. DOCA-salt mice exhibited diastolic dysfunction that was reversed after BH4 treatment. Diastolic sarcomere length (DOCA-salt 1.70±0.01 vs. DOCA-salt+BH4 1.77±0.01 μm, P<0.001) and relengthening (relaxation constant, τ, DOCA-salt 0.28±0.02 vs. DOCA-salt+BH4 0.08±0.01, P<0.001) were also restored to control by BH4 treatment. pCa50 for tension increased in DOCA-salt compared to sham, but reverted to sham levels after BH4 treatment. Maximum ATPase rate and tension cost (ΔATPase/ΔTension) decreased in DOCA-salt compared to sham, but increased after BH4 treatment. Cardiac MyBP-C glutathionylation increased in DOCA-salt compared to sham, but decreased with BH4 treatment. MyBP-C glutathionylation correlated with the presence of diastolic dysfunction.
Our results herein suggest that by depressing S-glutathionylation of MyBP-C, BH4 ameliorates diastolic dysfunction by reversing a decrease in cross-bridge turnover kinetics. These data provide evidence for modulation of cardiac relaxation by post-translational modification of myofilament proteins.
Here, we demonstrate that oral administration of BH4 improves diastolic dysfunction, reverses the changes in actin-myosin cross-bridge cycling, and decreases S-glutathionylated MyBP-C. Our results support the hypothesis that oxidative post-translational modifications and associated modulation of myofilament properties is a molecular mechanism for diastolic dysfunction.
All protocols were in accordance with the guidelines of the Animal Care and Use Committee of the University of Illinois and comply with the laws of the United States of America.
Previously, we have shown that the DOCA-salt mouse model leads to mild hypertension, NOS uncoupling, myocardial oxidative stress, and diastolic dysfunction (Reference 10). A gradual and mild elevation in blood pressure was induced by unilateral nephrectomy, subcutaneous implantation of a controlled release deoxycorticosterone acetate (DOCA) pellet (0.7 mg/d; Innovative Research of America, Sarasota, Fla.), and substituting drinking water with 1.05% saline. Control animals underwent a sham operation, had placebo pellet implantation, and received water without salt.
Mice were divided into two groups which received a control diet (sham N=7; DOCA-salt N=10) and two groups which received a BH4 supplemental diet of 5 mg BH4/day (Research Diets Inc, New Brunswick, N.J.; sham+BH4 N=8; DOCA-salt+BH4 N=8). The supplemental diet began on day 11 after surgery, and continued until day 18, when the mice were analyzed and sacrificed.
Mitral pulse wave Doppler flow and tissue Doppler imaging (TDI) were performed using the Vevo 770 high-resolution in vivo imaging system (Visual Sonics, Toronto, Canada) (Reference 10). Mice were anesthetized with 1-1.5% isoflurane until a heart rate of around 350-390 beats/min was achieved because measures of diastolic function are sensitive to heart rate and loading conditions. M-mode images in the parasternal long axis and the left ventricle (LV) short-axis views at the mid-papillary level were taken. Measurements were averaged from five consecutive beats during expiration. The images for each mouse were recorded for at least 5 s (30-40 cardiac cycles) from which three to five representative cycles with the highest quality imaging were selected. Percent fractional shortening (% FS) was calculated as 100×(LVEDd)−(LVESd)/(LVEDd) and percent LV ejection fraction (% EF) was calculated as 100×[(7/2.4+LVEDd)×LEDd3]−[(7/2.4+LVESd)×LVESd3]/[(7/2.4+LVEDd)×LEDd3]. Doppler measurements were made at the tips of the mitral leaflets for diastolic filling profiles in the apical four-chamber view. Mitral inflow velocities, peak early (E) and late (A) were measured by conventional pulsed-wave Doppler. TDI was used to determine the mitral annulus longitudinal velocities (Sm, E′, and A′) (Reference 10). Baseline images before treatment were acquired to confirm diastolic dysfunction in DOCA-salt mice. Subsequently, the mice were fed with BH4, followed by echocardiography at day 18.
Ventricular myocytes were isolated as previously described (Reference 10). Hearts were excised from anesthetized mice, perfused with buffer (in mmol/L: NaCl 113, KCl 4.7, Na2HPO4 0.6, KH2PO4 0.6, MgSO4 1.2, Phenol Red 0.032, NaHCO3 12, KHCO3 10, HEPES 10, Taurine 30, 2-3-butanedione monoxime 10) and digested with collagenase II (Worthington Biochemical Co. Lakewood, N.J.) for 7-8 min with 37° C. perfusion. Cardiomyocytes were washed with control buffers (in mmol/L: NaCl 133.5, KCl 4, Na2HPO4 1.2, HEPES 10, MgSO4 1.2 and 0.1% Bovine serum albumin) with serially increasing Ca2+ concentrations (0.2, 0.5, and 1 mmol/L). Then, myocytes were maintained in MEM medium (modified Eagle's medium with 1% insulin-transferrin-selenium, 0.1% bovine serum albumin, 1% glucose, and 1% penicillin/streptomycin) in a 95% O2/5% CO2 incubator at 37° C. until use.
The mechanical properties of the cardiomyocytes were assessed using an IonOptix Myocam System (IonOptix Inc., Milton, Mass.) as described previously (Reference 12). Unloaded cardiomyocytes isolated from each group of mice were placed on a glass slide and allowed to adhere for 5 min, then imaged with an inverted microscope and perfused with a normal Tyrode's buffer (in mmol/L: 133 NaCl, 5.4 KCl, 5.3 MgCl2, 0.3 Na2PO4, 20 HEPES, 10 glucose, pH 7.4) containing 1.2 mmol/L calcium at 37° C. with a temperature controller. Cardiomyocytes were paced with 10 V, 4 ms square wave pulses at 1.0 Hz, and sarcomere shortening and relengthening were assessed using the following indices: diastolic sarcomere length (SL), peak fractional shortening (FS, %), the prolonged relaxation time constant τ(a0+a1et/τ, t=time), relengthening time (s), and maximum relaxation velocity (dL/dt).
2,3-Butanedione monoxime (BDM), a cross-bridge inhibitor, was used to measure residual sarcomere length. BDM inhibits the Ca2+ regulated attachment of the cross-bridges and force-generation of the attached cross-bridges (Reference 16). Isolated single myocytes were loaded on an chamber and perfused with BDM (10 mM) in Tyrode's solution at 37° C. Sarcomere length was again measured while the myocytes were field-stimulated as described above.
Mice were anesthetized with pentobarbital (50 mg/kg IP), and the hearts were rapidly excised and rinsed in ice-cold relaxing solution (pH 7.0) composed of (in mM) 10 EGTA, 41.89 K-Prop, 6.57 MgCl2, 100 BES, 6.22 ATP, 5 Na azide, and 10 creatine phosphate. The solution also contained 1 μg/mL leupeptin, 2.5 μg/ml pepstatin A, and 50 μM phenylmethylsulfonyl fluoride. Left ventricular papillary muscles were dissected and fiber bundles were prepared as previously described (Reference 17). The fiber bundles were extracted overnight in relaxing solution plus 1% Triton X-100 at 4° C.
Force and ATPase rate were measured simultaneously as previously described (Reference 17) using an experimental apparatus also previously described (Reference 18). The fiber bundles were mounted between a force transducer and displacement motor using aluminum T-clips, and the sarcomere length was set to 2.2 μm using He—Ne laser diffraction (Reference 19). The width and diameter were each measured at three points along the fiber bundle. Force per cross-sectional area was used to determine tension. The fiber was initially contracted at a saturating calcium concentration (pCa 4.5) and sarcomere length was again adjusted to 2.2 μm. Sarcomere length remained constant throughout the rest of the experiment.
ATPase activity was measured at 20° C. as previously described (References 17 and 20) and calibrated with rapid injections of ADP (0.5 nmol) with a motor-controlled syringe. The fiber was placed in relaxing solution for 2 min, then in the pre-activation solution for 2-3 min each time before being placed in the activating solution for 1-2 min (until stabilization of force) and then quickly returned to the relaxing solution. Various contraction-relaxation cycles were carried out using different ratios of total calcium concentration to total EGTA concentration. The final contraction was again at pCa 4.5.
In one series of experiments, we employed Pro-Q Diamond (Invitrogen) gel stain to determine changes in phosphorylation of myofilament proteins. We also employed site specific antibodies for MyBP-C (anti-phospho-peptide-Ser282) and for cTnI (anti-phopho-Ser23/Ser24). Detailed methods are presented below.
Myofibrils were prepared from DOCA-salt and sham model hearts, and pellets were solubilized in a non-reducing 2× Laemmli buffer (4% SDS, 20% glycerol, 0.004% bromophenol blue, and 0.125 M Tris HCl pH 6.8). 25 mM N-ethylmaleimide (NEM) was added to the standard rigor buffer with Triton X-100, the standard rigor wash buffer and the 2× Laemmli buffer. (Reference 21). Using the protein concentration determined from an RC-DC (Bio-Rad) assay, 40 pg of total protein was applied to a 12% SDS-PAGE gel and transferred onto a 0.2 μm PVDF membrane. The blot was blocked in 5% nonfat dry milk with 2.5 mM NEM for 1 h. Anti-glutathione mouse monoclonal primary antibody (Virogen) was used at 1:1000 dilution along with anti-mouse HRP-conjugated secondary antibody (Sigma) at 1:100,000 dilution to detect for S-glutathionylation (Reference 22). Optical density of the bands was measured with ImageQuant TL (GE Healthcare) and exported to Excel for further analysis.
Echocardiography, sarcomere shortening, skinned fiber tension, and ATPase measurements, as well as post-translational modifications of myofilament proteins, were statistically analyzed by two-way ANOVA followed by student's t test using JMP statistical software. Analysis of the relation between Ca2+ and tension or ATPase activity was fitted using a modified Hill equation as described previously [20]. Analysis of the relation between MyBP-C glutathionylation and echocardiographic, E/E′ ratio was correlated in linear regression analysis. A value of P<0.05 was considered significantly different. Data are presented as means±SEM.
Pro-Q Diamond (Invitrogen) gel stain was used to detect changes in phosphorylation states of the proteins. Myofibrils were prepared from DOCA-salt and sham models of the mice hearts, and pellets were solubilized in a non-reducing 2× Laemmli buffer (4% SDS, 20% glycerol, 0.004% bromophenol blue, and 0.125 M Tris HCl pH 6.8) (Reference 21). 25 mM N-ethylmaleimide (NEM) was added to the standard rigor buffer with Trition X-100, the standard rigor wash buffer and the 2× Laemmli buffer. An RC-DC assay (Bio-Rad) was used to determine protein concentrations. Samples were diluted at 1:1 ratio in reducing sample buffer (8 M urea, 2 M thiourea, 0.05 M tris pH 6.8, 75 mM DTT, 3% SDS, and 0.05% bromophenol blue) (Reference 41) and approximately 10 pg of protein was loaded on to a 12% resolving 1D SDS-PAGE gel. (References 42 and 43). The gels were stained and destained with Pro-Q Diamond according to the manufacturer's recommendations prior to imaging with a Typhoon 9410 scanner (GE Healthcare). Coomassie R-250 staining was used to normalize protein load to both MLC1 and the whole lane. Optical density of the proteins was determined using ImageQuant TL (GE Healthcare) software and results were exported to Excel for further analysis.
Myofibrils were prepared from DOCA-salt and sham mice hearts with or without BH4 treatment (Reference 21) and pellets were solubilized in a reducing 2× Laemmli buffer (4% SDS, 20% glycerol, 0.004% bromophenol blue, 75 mM DTT and 0.125 M Tris HCl pH 6.8). An RC-DC assay (Bio-Rad) was used to determine protein concentrations. Samples were diluted at 1:1 ratio in reducing sample buffer (8 M urea, 2 M thiourea, 0.05 M tris pH 6.8, 75 mM DTT, 3% SDS, and 0.05% bromophenol blue) (Reference 41). Approximately 10 μg of protein was applied on to a 12% resolving 1D SDS-PAGE gel (References 42 and 43) and transferred onto a 0.2 pm PVDF membrane. The blot was blocked in 5% nonfat dry milk for 1 h. Anti-phospho-ser282-MyBP-C rabbit polyclonal antibody antibody (ENZO) and MyBP-C rabbit antidoby (Santa Cruz) was used at 1:1000 dilution along with anti-rabbit HRP-conjugated secondary antibody (Sigma) at 1:100,000 dilution to detect serine 282 site specific phosphorylation of MyBP-C. Anti-phospho-ser23/24-cTn1 rabbit polyclonal antibody (Cell Signaling) was used at 1:1000. Coomassie R-250 staining was used to normalize protein load to both actin and the whole lane. Optical density of the bands was measured with Image J and exported to Excel for further analysis.
Improvement in Diastolic Function with BH4
Ten days after surgery, we employed echocardiography to characterize the diastolic dysfunction. Treatment with a BH4 supplemental diet was begun on post-operative day 11, and echocardiography was repeated on postoperative day 18. The results can be seen in
Mitral Doppler flow was measured at comparable heart rates (˜average 370 beats/min) in all mice (Reference 10). As we have reported in this model, mitral E velocity, A velocity, and the E/A ratio were not significantly changed in all groups (
Improvement in Cardiomyocyte Parameters of Relaxation with BH4
To confirm diastolic relaxation impairment in the model, we isolated single myocytes from each group and measured sarcomeric contraction and relaxation function, as seen in
To determine whether increased diastolic tension could be explained by active cross-bridge cycling, we treated the myocytes with BDM, a non-competitive inhibitor of active force-generation (Reference 16). Treatment of isolated myocytes with BDM (10 mM) increased residual sarcomere length in the sham and DOCA-salt groups. Treatment of either group with BH4 resulted in significant relaxation as measured by sarcomere length. After BH4 treatment, BDM had no effect, suggesting that BH4 facilitated cross-bridge dissociation (
In order to assess the relation between myocardial diastolic dysfunction and changes in myofilament properties, we performed analysis of tension and ATPase activity in skinned fiber preparations (
Maximum ATPase rate was also significantly reduced in DOCA-salt mice. This was accompanied by modest changes in maximum tension, pCa50 for tension and ATPase rate. BH4 treatment increased maximum tension and ATPase rates in both sham and DOCA-salt mice, again with modest changes in pCa50 and significant changes in tension cost that varied in DOCA-salt versus sham mice. (
In one set of experiments, we determined potential modifications in phosphorylation of myofilament proteins employing Pro-Q diamond phospho-protein gel stain. With BH4 treatment in the DOCA-salt mice, there was a decrease in phosphorylation of major myofialment proteins, MyBP-C, TnT3, cTnT4, MLC2 and titin, and no change in cTnl phosphorylation. The decreases in phosphorylation would tend to slow cross-bridge kinetics or increase diastolic stiffness, and thus are not likely to account for the reversal of effects of DOCA-salt on diastolic dysfunction with BH4 treatment. To further test this conclusion, we determined the level of site-specific phosphorylation changes in both MyBP-C and cTnl (
In view of our earlier findings indicating an increase in MyBP-C S-glutathionylation in cardiac myofilaments from DOCA-salt mice, we determined whether the BH4 diet could reverse this modification. Representative gels and plotted data normalized to total protein loadings are shown in
Results presented here provide new understanding of the role of cardiac myofilaments in the pharmacology and therapeutic efficacy of BH4 for the treatment of diastolic dysfunction induced by pressure-overload. Overall, our results indicate that hypertension-associated diastolic dysfunction in this model likely arises mainly from a reduction in cross-bridge turnover kinetics and that administration of BH4 results in amelioration of diastolic dysfunction by speeding these kinetics. Although correlative, our results support the hypothesis that changes in cross-bridge kinetics correlate with MyBP-C S-glutathionylation and that this oxidative modification may be responsible for the changes in cardiac dynamics. To the best of our knowledge, the present study is the first to report that treatment with BH4 reduces increased levels of MyBP-C S-glutathionylation. Therefore, this post-translational modification may serve as a novel marker useful for the identification and treatment of diastolic heart dysfunction. Unlike in our previous study with ranolazine for the treatment of diastolic dysfunction, BH4 reversed the glutathionylation of MyBP-C, suggesting that these two drugs work on the same disorder by different mechanisms (Reference 12).
Apart from our previous study indicating that S-glutathionylation correlated with changes in diastolic dysfunction and in tension cost, there is considerable evidence that modifications of MyBP-C affect diastolic function. Mutations in MyBP-C are known to induce diastolic dysfunction (Reference 25). MyBP-C is also a substrate for multiple kinases, including protein kinase (PK)A, PKC, PKD, and CaMKII (Reference 26). MyBP-C and its dephosphorylation have been shown to be associated with end stage human heart failure (Reference 27). MyBP-C dephosphorylation has also been associated with its degradation (References 26, 28-30), thick filament disruption, and contractile dysfunction (References 26, 28, 30). Phosphorylation of MyBP-C by PKA accelerates cross-bridge turnover rates (Reference 26). Interestingly, a non-PKA-phosphorylatable truncated mutant of MyBP-C (AIIP-:[t/t]) exhibited a dilated LV chamber diameter, increased septal thickness, and depressed systolic function. This model also exhibited significant diastolic dysfunction because of slower cross-bridge cycling in the absence of baseline phosphorylation of MyBP-C (Reference 31). In general, our results fit with data in these studies indicating that effects of post-translational modifications in MyBP-C may be more prominently involved in altered cross-bridge kinetics and muscle dynamics than alterations in Ca-sensitivity. For example, employing loss of function models, Stelzer et al. reported that, in the intact myocardium, PKA phosphorylation of MyBP-C was a more prominent determinant of contraction and relaxation kinetics than phosphorylation of cardiac troponin I (cTnl), which was a more prominent determinant of Ca-sensitivity (Reference 32).
Nevertheless, in our experiments, MyBP-C phosphorylation did not correlate with diastolic dysfunction or BH4 efficacy. In fact, compared to DOCA-salt myofilaments, the myofilaments from the DOCA-BH4 treated hearts had reduced phosphorylation of MyBP-C as well as TnT, and MLC2. Yet BH4 did not affect the phosphorylation of these proteins in the shams. A limitation of the study is that Pro-Q analysis measures total phosphorylation of a given protein, and MyBP-C contains multiple phosphorylation sites, the function of which are poorly understood. Thus, although we cannot exclude that site-specific phosphorylation may have contributed to diastolic dysfunction or the effect of BH4, overall our data indicate that phosphorylation is not likely to contribute substantially to our findings of decreased tension cost and cross-bridge kinetics in the DOCA-salt myofilaments or to the amelioration of this effect with BH4 treatment.
In addition to altered cross-bridge kinetics as a potential mechanism of diastolic dysfunction, modifications in sarcomeric diastolic function may be significantly affected by modifications in titin (References 33 and 34). In view of the potential modulation of extensibility by titin phosphorylation by protein kinase G (References 33 and 35), NO has been suggested to play an important role in regulating diastolic tone and ventricular filling through a cGMP-PKC dependent pathway (Reference 36). Moreover, PKG activation has been suggested to affect the reduction of Ca2+ sensitivity through Tnl phosphorylation at Ser23/24 and an increase in cross-bridge cycling rate, leading to acceleration of relaxation (References 37 and 38). However, in the present study, both titin and Tnl phosphorylation were not changed by BH4 treatment in DOCA-salt mice suggesting another mechanism may be involved in the relaxation improvement via BH4 in this model.
An important issue is the molecular mechanism of the effect of S-glutathionylation on MyBP-C function. Possible mechanisms are couched in terms of current hypotheses as to how MyBP-C controls cross-bridge kinetics. One plausible mechanism is that the radial disposition of MyBP-C in relation to the thick filament proper is a determinant of the rates of entry of the cross-bridges into and out of the cross-bridge cycle. Proximity of cross-bridges has been demonstrated to be increased by PKA-dependent phosphorylation (Reference 39). There is also evidence that MyBP-C directly interacts with actin in the thin filaments, and it is also plausible that modulation of thin filaments may result in increased cross-bridge kinetics (Reference 40). Whatever the case, our data indicate that modification of one or more cysteine residues of MyBP-C under oxidative control by S-glutathionylation is likely to alter the proximity of the cross-bridges to or their interactions with the thin filament. In the case of the DOCA-salt model, the modification is maladaptive and induces a diastolic abnormality. It is interesting to speculate that oxidative modification of MyBP-C may also serve as an adaptive mechanism in homeostasis, which modulates cardiac relaxation reserve by controlling cross-bridge kinetics.
In summary, hypertension-induced diastolic dysfunction was characterized by reduced cross-bridge kinetics and tension cost that was reversed by BH4. The effect of BH4 correlated with glutathionylation of MyBP-C, suggesting that this post-translational modification may lead to diastolic dysfunction and that BH4 treatment may work by preventing this oxidative modification.
Previously, we demonstrated that the depletion of NO bioavailability caused by increased reactive oxygen species (ROS) induced diastolic dysfunction with preserved systolic function through nitric oxide synthase (NOS) uncoupling in the heart. Depletion of tetrahydrobiopterin (BH4) causes NOS uncoupling, resulting in relaxation impairment of the heart. Mitochondria are one of the major cardiac oxidative stress sources, and manganese superoxide dismutase (MnSOD) is a mitochondrial antioxidant enzyme. In the present study, we sought to determine whether heterozygous knockout of the MnSOD gene (Sod2+/−) would be associated with diastolic dysfunction (DD) that could be ameliorated by BH4.
Echocardiography was used to determine DD in heterozygous MnSOD knockout mice. The mitral annulus longitudinal velocities (E′, and A′) were determined by pulsed-wave tissue Doppler from the apical four-chamber view. Mitochondrial ROS were measured by confocal microscopy and flow cytometry from isolated cardiomyocytes using MitoSOX Red. NO was measured by DAF-FM and by the Griess reaction. Contraction and relaxation impairment were assessed by lonOptix System.
Mitochondrial ROS were elevated by 2.6-fold and NO level was reduced by 0.77-fold in cardiomyocytes from MnSOD deficient mice. The ratio of mitral annulus longitudinal velocities (E′/A′) were significantly reduced indicating DD at MnSOD deficient mice (MnSOD 0.88±0.14 vs. WT 1.11±0.11). Resting sarcomere length was significantly reduced in MnSOD deficient cardiomyocytes compared to WT (MnSOD 1.68±0.01 μm vs. WT 1.84±0.01 μm, P<0.001) and the relaxation constant (tau) was significantly increased (MnSOD 0.12±0.01 vs. WT 0.09±0.01, P<0.05). BH4 treatment improved resting sarcomere length (1.77±0.01 μm, P<0.001) and tau (0.73±0.01, P<0.001) compared to MnSOD.
MnSOD deficiency was associated with impaired cardiac relaxation indicating DD, which could be improved with BH4 treatment.
While this invention has been described as having preferred sequences, ranges, steps, order of steps, materials, structures, shapes, configurations, features, components, or designs, it is understood that it is capable of further modifications, uses and/or adaptations of the invention following in general the principle of the invention, and including such departures from the present disclosure as those come within the known or customary practice in the art to which the invention pertains, and as may be applied to the central features hereinbefore set forth, and fall within the scope of the invention and of the limits of the appended claims.
The following references, and those cited in the disclosure herein, are hereby incorporated herein in their entirety by reference.
This is a continuation-in-part (CIP) application of U.S. application Ser. No. 11/895,883, filed Aug. 27, 2007, which claims the priority benefit of U.S. Provisional Patent Application Ser. No. 60/840,368, filed Aug. 25, 2006, both are hereby incorporated herein in their entirety by reference. This application further claims the priority benefit of U.S. Provisional Patent Application Ser. No. 61/552,500, filed Oct. 28, 2011, which is also hereby incorporated herein in its entirety by reference.
The work leading to the present invention was supported by NIH/NHLBI grants RO1 HL022231, RO1 HL064035, PO1 HL062426 to RJ S, and NIH/NHLBI grants RO1 HL085558, RO1 HL073753, PO1 HL058000, and a Veterans Affairs MERIT grant to SCD. MMM was supported by NIH T32 HL07692-16-20; DMT was supported by University of Illinois at Chicago Center for Clinical and Translational Science (Award Number UL1 RR029879) from the National Center for Research Resources, and by a University of Illinois at Chicago Fellowship. The U.S. Government therefore has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 60840368 | Aug 2006 | US | |
| 61552500 | Oct 2011 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11895883 | Aug 2007 | US |
| Child | 13658943 | US |
